Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis

DOI Web Site 被引用文献7件
  • Riccardo Candido
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Terri J. Allen
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Markus Lassila
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Zemin Cao
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Vicki Thallas
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Mark E. Cooper
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.
  • Karin A. Jandeleit-Dahm
    From the Vascular Division, Baker Heart Research Institute, Melbourne, Victoria, Australia.

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> It remains controversial whether specific blockade of the renin-angiotensin system confers superior antiatherosclerotic effects over other antihypertensive agents in diabetes. Therefore, the aim of this study was to compare equihypotensive doses of the angiotensin II subtype 1 (AT <jats:sub>1</jats:sub> ) receptor blocker irbesartan with the calcium antagonist amlodipine on diabetes-induced plaque formation in the apolipoprotein E (apoE)–null mouse and to explore molecular and cellular mechanisms linked to vascular protection. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> Diabetes was induced by injection of streptozotocin in 6-week-old apoE-null mice. Diabetic animals were randomized to no treatment, irbesartan, or amlodipine for 20 weeks. Diabetes was associated with an increase in plaque area and complexity in the aorta in association with a significant increase in aortic AT <jats:sub>1</jats:sub> receptor expression, cellular proliferation, collagen content, macrophage- and α-smooth muscle actin–positive cell infiltration, as well as an increased expression of platelet-derived growth factor-B (PDGF-B), monocyte chemoattractant protein-1 (MCP-1), and vascular cell adhesion molecule-1 (VCAM-1). Irbesartan but not amlodipine treatment attenuated the development of atherosclerosis, collagen content, cellular proliferation, and macrophage infiltration as well as diabetes-induced AT <jats:sub>1</jats:sub> receptor, PDGF-B, MCP-1, and VCAM-1 overexpression in the aorta despite similar blood pressure reductions by both treatments. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Diabetes-associated atherosclerosis is ameliorated by AT <jats:sub>1</jats:sub> receptor blockade but not by calcium channel antagonism, providing further evidence for the vascular renin-angiotensin system playing a pivotal role in the development and acceleration of atherosclerosis in diabetes. </jats:p>

収録刊行物

  • Circulation

    Circulation 109 (12), 1536-1542, 2004-03-30

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ